A roundtable discussion of anemia management in myeloproliferative neoplasms (MPNs), featuring moderator John Mascarenhas, MD, Mount Sinai; Andrew Kuykendall, MD, Moffitt Cancer Center; and Gabriela Hobbs, MD, Massachusetts General Research Institute.
In this segment, the panel discusses the use of anemia-directed agents such as luspatercept in patients with myelofibrosis who are being treated with ruxolitinib. They take a closer look at the RR6 prognostic model, which assesses patient response to ruxolitinib after six months, considering factors such as transfusion dependence, suboptimal dosing, and spleen response. The panel also discussed whether adding anemia-targeted therapies can improve outcomes by mitigating these risk factors.
